

Supplementary Information

Spirocitrinols A and B, Citrinin Derivatives with a Spiro[chromane-2,3'-isochromane] Skeleton from *Penicillium citrinum*

Junjie Tong,^{†^{ab}} Yang Zhang,^{†^c} Yang Xu,^d Yangyang Han,^d Chuan Li,^{*^b} Wenying Zhuang,^d and Yongsheng Che^{*^{ab}}

Affiliation

^a Tianjin University of Traditional Chinese Medicine, Tianjin 300193, People's Republic of China

^b NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, People's Republic of China

^c State Key Laboratory of Toxicology & Medical Countermeasures, Beijing Institute of Pharmacology & Toxicology, Beijing 100850, People's Republic of China

^d State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, People's Republic of China

Correspondence

* To whom correspondence should be addressed.
Yongsheng Che. E-mail: ysche@imb.cams.cn;
Chuan Li. E-mail: lichuan@imb.cams.cn.

Contents	Page
1) Table S1. NMR data for 1 in methanol- <i>d</i> ₄	3
2) Figure S1. ¹ H NMR spectrum of spirocitrinol A (1 ; 600 MHz, DMSO- <i>d</i> ₆)	4
3) Figure S2. ¹³ C NMR spectrum of spirocitrinol A (1 ; 150 MHz, DMSO- <i>d</i> ₆)	5
4) Figure S3. HSQC spectrum of spirocitrinol A (1 ; 600 MHz, DMSO- <i>d</i> ₆)	6
5) Figure S4. HMBC spectrum of spirocitrinol A (1 ; 600 MHz, DMSO- <i>d</i> ₆)	7
6) Figure S5. NOESY spectrum of spirocitrinol A (1 ; 600 MHz, DMSO- <i>d</i> ₆)	8
7) Figure S6. HRESIMS spectrum of spirocitrinol A (1)	9
8) Figure S7. ¹ H NMR spectrum of spirocitrinol B (2 ; 600 MHz, DMSO- <i>d</i> ₆)	10
9) Figure S8. ¹³ C NMR spectrum of spirocitrinol B (2 ; 150 MHz, DMSO- <i>d</i> ₆)	11
10) Figure S9. HSQC spectrum of spirocitrinol B (2 ; 600 MHz, DMSO- <i>d</i> ₆)	12
11) Figure S10. HMBC spectrum of spirocitrinol B (2 ; 600 MHz, DMSO- <i>d</i> ₆)	13
12) Figure S11. NOESY spectrum of spirocitrinol B (2 ; 600 MHz, DMSO- <i>d</i> ₆)	14
13) Figure S12. NOE difference spectrum of spirocitrinol B (2 ; 600 MHz, DMSO- <i>d</i> ₆)	15
14) Figure S13. HRESIMS spectrum of spirocitrinol B (2)	16
15) Figure S14. The optimized conformers of 1a	17
16) Figure S15. The optimized conformers of 2a	18
17) Figure S16. The ITS rDNA sequence data of <i>Penicillium citrinum</i>	19
18) Figure S17. Cytotoxic effects of compounds 1 and 2 against seven tumor cell lines	19
19) Scheme S1. Plausible biosynthetic pathways for compounds 1 and 2	20

Table S1. NMR Data for **1** in Methanol-*d*₄

no	1		
	δ_{C}^a , mult.	δ_{H}^b (<i>J</i> in Hz)	HMBC
1	137.3, qC		
2	116.0, qC		
3	156.6, qC		
4	100.9, CH	6.01, s	2, 3, 5, 6
5	150.8, qC		
6	111.6, qC		
7	61.1, CH	4.99, dd (4.6, 12.0)	10
8	76.6, CH	4.13, m	7, 9
9	36.2, CH	2.73, m	1, 8
10a	37.0, CH ₂	2.44, dd (4.8, 12.0)	6, 7, 21
10b		1.75, t (12.0)	6, 7, 21
11	18.8, CH ₃	1.41, d (6.6)	8, 9
12	22.8, CH ₃	1.23, d (7.2)	1, 8, 9
13	10.4, CH ₃	2.05, s	1, 2
14	135.0, qC		
15	115.4, qC		
16	153.3, qC		
17	111.9, qC		
18	149.3, qC		
19	113.6, qC		
20a	62.0, CH ₂	4.65, d (14.4)	14, 19
20b		4.82, d (15.0)	14, 19, 21
21	102.4, qC		
22	39.6, CH	2.92, m	10, 14, 19, 21, 23
23	18.7, CH ₃	1.18, d (6.6)	
24	10.8, CH ₃	2.13, s	14, 15, 16
25	9.2, CH ₃	2.15, s	17, 18

^a Recorded at 150 MHz. ^b Recorded at 600 MHz

Figure S1. ^1H NMR Spectrum of Spirocitrinol A (**1**; 600 MHz, $\text{DMSO}-d_6$)




Figure S2. ^{13}C NMR Spectrum of Spirocitrinol A (**1**; 150 MHz, $\text{DMSO}-d_6$)




Figure S3. HSQC Spectrum of Spirocitrinol A (**1**; 600 MHz, DMSO-*d*₆)




Figure S4. HMBC Spectrum of Spirocitrinol A (**1**; 600 MHz, DMSO-*d*₆)




Figure S5. NOESY Spectrum of Spirocitrinol A (**1**; 600 MHz, DMSO-*d*₆)




Figure S6. HRESIMS Spectrum of Spirocitrinol A (**1**)




Figure S7. ^1H NMR Spectrum of Spirocitrinol B (**2**; 600 MHz, $\text{DMSO}-d_6$)




Figure S8. ^{13}C NMR Spectrum of Spirocitrinol B (**2**; 150 MHz, $\text{DMSO}-d_6$)




Figure S9. HSQC Spectrum of Spirocitrinol B (**2**; 600 MHz, DMSO-*d*₆)




Figure S10. HMBC Spectrum of Spirocitrinol B (**2**; 600 MHz, DMSO-*d*₆)




Figure S11. NOESY Spectrum of Spirocitrinol B (**2**; 600 MHz, DMSO-*d*₆)




Figure S12. NOE Difference Spectrum of Spirocitrinol B (**2**; 600 MHz, DMSO-*d*₆)




Figure S13. HRESIMS Spectrum of Spirocitrinol B (2)




Figure S14. The Optimized Conformers of **1a**




Figure S15. The Optimized Conformers of **2a**





Figure S16. The ITS rDNA Sequence Data of *Penicillium citrinum*

CCACCTCCCACCGTGTGCCGAACCTATGTTGCCTGGCGGGCCCCGCGCCCG
 CCGACGGCCCCCTGAACGCTGTCTGAAGTTGCAGTCTGAGACCTATAACGAAAT
 TAGTTAAAACCTTCACAACACGGATCTCTGGTCCGGCATCGATGAAGAACGCAG
 CGAAATGCGATAACTAATGTGAATTGCAGAATTCACTGAGTCTTGA
 ACGCACATTGCGCCCTCTGGTATTCCGGAGGGCATGCCTGTCCGAGCGTCATTGC
 TGCCCTCAAGCCGGCTTGTGTGG

Figure S17. Cytotoxic Effects of Compounds **1** and **2** against Seven Tumor Cell Lines



Scheme S1. Plausible Biosynthetic Pathways for Compounds **1** and **2**

